M. Bafadhel (Oxford (Oxfordshire), United Kingdom), E. Márquez Martín (Sevilla, Spain)
Adding budesonide to formoterol reduces risk of clinically important deteriorations (CID) in moderate to very severe COPD
M. Bafadhel (Oxford, United Kingdom), D. Singh (Manchester, United Kingdom), C. Jenkins (Sydney, Australia), S. Peterson (Lund, Sweden), T. Bengtsson (Lund, Sweden), P. Wessman (Gothenburg, Sweden), M. Fagerås (Gothenburg, Sweden)
|    |
Prognostic significance of obstruction severity in COPD patients admitted to coronary artery bypass grafting.
E. Klester (Kazan, Russian Federation), K. Klester (Barnaul, Russian Federation), A. Balitskaya (Barnaul, Russian Federation), A. Berdyugina (Barnaul, Russian Federation), V. Elykomov (Barnaul, Russian Federation), A. Zateev (Barnaul, Russian Federation)
|  |
Monitoring antioxidant enzyme activity in patients with COPD exacerbations
B. Antus (Budapest, Hungary), C. Paska (Budapest, Hungary), I. Barta (Budapest, Hungary)
| |
GOLD ABCD assessment tool: Comparison of 2013 and 2017 classifications in the UK Clinical Practice Research Datalink (CPRD)
A. Mathioudakis (Manchester, United Kingdom), J. Vestbo (Manchester, United Kingdom), A. Gayle (Bracknell, United Kingdom), S. Dickinson (Bracknell, United Kingdom), K. Morris (Bracknell, United Kingdom), S. Webster (Bracknell, United Kingdom), C. Poole (Bracknell, United Kingdom)
| |
Serum amyloid A in patients with stable chronic obstructive pulmonary disease
M. Maskey-Warzechowska (Warsaw, Poland), R. Rubinsztajn (Warsaw, Poland), T. Przybylowski (Warsaw, Poland), K. Karwat (Warsaw, Poland), P. Nejman-Gryz (Warsaw, Poland), R. Chazan (Warsaw, Poland)
| |
Relationship between Volatile Organic Compounds (VOCs) in exhaled breath determined by Proton Transfer Reaction Time of Flight Mass Spectrometry (PTR-TOF-MS), clinical characteristics and airway inflammation in COPD
L. Carr (Leicester, United Kingdom), L. Bryant (Leicester, United Kingdom), A. Yousuf (Leicester, United Kingdom), R. Cordell (Leicester, United Kingdom), M. Wilde (Leicester, United Kingdom), S. Siddiqui (Leicester, United Kingdom), P. Monks (Leicester, United Kingdom), C. Brightling (Leicester, United Kingdom)
| |
Treatment response in COPD – does FEV1 say it all? An analysis of the CRYSTAL trial
T. Greulich (Marburg, Germany), C. Vogelmeier (Marburg, Germany), A. Mackay (London, United Kingdom), N. Lossi (Nuernberg, Germany), M. Aalamian-Mattheis (Basel, Switzerland), X. Nunez (Barcelona, Spain), V. Pagano (Barcelona, Spain), F. Patalano (Basel, Switzerland), A. Clemens (Basel, Switzerland), K. Kostikas (Basel, Switzerland)
| |
Longitudinal measurements of blood eosinophils in relation to COPD outcomes
J. Ellingsen (Uppsala, Sweden), C. Janson (Uppsala, Sweden), K. Bröms (Gävle, Sweden), K. Lisspers (Uppsala, Sweden), B. Ställberg (Uppsala, Sweden), M. Högman (Uppsala, Sweden), A. Malinovschi (Uppsala, Sweden)
| |
Eosinophils and acute exacerbation of COPD: a potent biomarker for patients at increased risk. Preliminary reports.
E. Papathanassiou (Athens , Greece), A. Papaioannou (Athens , Greece), G. Hillas (Athens , Greece), E. Mizi (Athens , Greece), P. Bakakos (Athens , Greece), V. Apollonatou (Athens , Greece), G. Verykokou (Athens , Greece), N. Roussakis (Athens , Greece), Z. Tsilogianni (Athens , Greece), K. Kostikas (Athens , Greece), S. Papiris (Athens , Greece), S. Loukides (Athens , Greece)
| |
Impact of Eosinophilia and Time on Lung Function Decline in Adult Asthma
S. Graff (Liège, Belgium), C. Moermans (Liège, Belgium), R. Louis (Liège, Belgium), F. Schleich (Liège, Belgium)
| |
EOSINOPHIL COUNT AND FeNO AS PREDICTORS OF EXACERBACTIONS IN COPD
B. Alcazar Navarrete (Loja, Spain), O. Ruiz Rodriguez (Loja, Spain), P. Conde Baena (Loja, Spain), P. Romero Palacios (Granada, Spain)
| |
Determinants of FENO in COPD with regard to current smoking
M. Högman (Uppsala, Sweden), C. Janson (Uppsala, Sweden), K. Lisspers (Uppsala, Sweden), K. BröMs (Gävle, Sweden), B. StäLlberg (Uppsala, Sweden), A. Malinovschi (Uppsala, Sweden)
| |
Use of Inhaled corticosteroid (ICS)-containing regimen for COPD patients with high or low blood eosinophilia: A meta-analysis
J. Chua (Manila, Philippines), A. Albay (Manila, Philippines), M. Zamora (Manila, Philippines)
| |
COPD: Are beliefs about inhaled medication associated with patients’ inhaler technique?
A. Silva Duarte De Araújo (Braga, Portugal), P. Teixeira (Braga, Portugal), V. Hespanhol (Porto, Portugal), J. Correia-De-Sousa (Braga, Portugal)
| |
Overexpression of chitotriosidase and YKL-40 in serum and sputum in healthy smokers and patients with chronic obstructive pulmonary disease
S. Majewski (Lodz, Poland), D. Tworek (Lodz, Poland), K. Szewczyk (Lodz, Poland), Z. Kurmanowska (Lodz, Poland), J. Kiszalkiewicz (Lodz, Poland), E. Brzezianska-Lasota (Lodz, Poland), H. Jerczynska (Lodz, Poland), A. Antczak (Lodz, Poland), W. Piotrowski (Lodz, Poland), P. Górski (Lodz, Poland)
| |
Significance of serum YKL-40, S100A8, S100A9, calprotectin, periostin and LRG1 levels in patients with newly diagnosed, controlled and uncontrolled asthma
B. Gemicioglu (Istanbul, Turkey), O. Yasar (Istanbul, Turkey), T. Akcay (Istanbul, Turkey)
| |